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A B S T R A C T
Antiepileptic drugs (AEDs) are known to have endocrine side effects in both men and women. These can
affect fertility, sexuality, thyroid function, and bone health, all functions of major importance for well-
being and quality of life. The liver enzyme inducing antiepileptic drugs (EIAEDs), like phenobarbital,
phenytoin, and carbamazepine, and also valproate (VPA), a non-EIAED, are most likely to cause such side
effects. AED treatment can alter the levels of different sex hormones. EIAEDs increase sex hormone
binding globulin (SHBG) concentrations in both men and women. Over time, this elevation can lead to
lower levels of bioactive testosterone and estradiol, which may cause menstrual disturbances, sexual
problems, and eventually reduced fertility. VPA can cause weight gain in both men and women. In
women, VPA can also lead to androgenization with increased serum testosterone concentrations,
menstrual disturbances, and polycystic ovaries.
Lamotrigine has not been shown to result in endocrine side effects. The newer AEDs have not yet been
thoroughly studied, but case reports indicate that some of these drugs could also be suspected to cause
such effects if endocrine changes commence after treatment initiation.
It is important to be aware of possible endocrine side effects of AEDs as they can have a major impact
on quality of life, and are, at least partly, reversible after AED discontinuation.
 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.
Contents lists available at ScienceDirect
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Epilepsy can have major impacts on several important aspects
of life. The severity of the disease varies from good seizure control
or seizure freedom (50–60%) with minor side effects from
medication, to a debilitating disease with several daily seizures,
the need for polytherapy, the occurrence of major side effects, and
problems with drug interactions. Many patients also suffer from an
underlying brain disease and co-morbidity, with depression or
psychiatric disorders, for example, occurring frequently.
The epilepsy itself, with frequent epileptic discharges, can
interact with cerebral function and affect memory and other
cognitive aspects. Alterations in hormone levels are a direct effect
of epileptic discharges, both in animals and humans [1–5].
Distinguishing the side effects of antiepileptic drugs (AEDs)
from the many other factors that inﬂuence the patients can be
difﬁcult. In vitro experimental studies, in vivo animal studies, and* Corresponding author at: Department of Neurology, Oslo University Hospital –
Rikshospitalet, PO Box 4950 Nydalen, 0424 Oslo, Norway. Tel.: +47 23073580;
fax: +47 23074891.
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1059-1311/ 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.studies in humans using the same medication for diagnoses other
than epilepsy, can be helpful. In order to avoid the possible
complexity from multiple interactions, monotherapy studies are
important.
Despite these investigative difﬁculties, AEDs have been clearly
demonstrated to have several hormonal side effects that can
inﬂuence important areas in life, such as fertility, sexual function,
and bone health. Some side effects may also be of a more cosmetic
nature, such as weight gain, hair loss, acne, or a more masculine
hair distribution in women. The various drugs affect the hormonal
system differently, and cause speciﬁc and different types of
hormonal disturbances.
2. Reproductive endocrine function in men
2.1. Enzyme-inducing drugs
The AEDs phenobarbital (PB), phenytoin (PHT), and carbamaz-
epine (CBZ) are all inducers of hepatic microsomal enzymes, and
thus accelerate the metabolism of other drugs, and also the
breakdown and production of sex hormone binding globulin
(SHBG). This increases SHBG concentrations and reduces concen-
trations of free, circulating androgen and estrogen, resulting in
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Elevated estradiol levels have also been found in men with
epilepsy taking PHT [7,10].
Low serum dehydroepiandrosterone sulfate (DHAES) concen-
trations have also been reported in men and women taking PHT
and CBZ [6,8,11]. DHAES is a weak androgen that is secreted from
the adrenal cortex, but the clinical implication of low DHAES levels
is unknown.
Associations between high estradiol levels and sexual dysfunc-
tion have been found in men taking PHT [10]. In some men, sexual
dysfunction has also been described after long-term CBZ or PHT
treatment and is related to low bioactive testosterone levels [12].
Furthermore, both CBZ and PHT have been associated with changes
in semen quality [13] and CBZ has been linked with reduced sperm
motility and increased frequency of morphologically abnormal
sperm [14,15].
Despite these ﬁndings, there is no obvious signiﬁcant reduction
in fertility in patients using enzyme-inducing AEDS (EIAEDs) [16].
Oxcarbazepine: Oxcarbazepine (OXC) has a different metabolic
pathway to that of CBZ. Instead of oxidation, OXC is metabolized by
reduction to its active metabolite, 10,11-dihydro-10-hydroxy-carba-
mazepine, and induces the liver P450 enzyme system only at high
doses [17]. OXC taken in high doses may affect serum testosterone and
SHBG levels, and may also induce changes in sperm morphology [18].
However, these ﬁndings should be conﬁrmed in further studies before
conclusions on their clinical signiﬁcance can be reached.
2.2. Valproate
Valproate (VPA) does not induce liver enzymes, but, neverthe-
less, does reduce serum gonadotropin levels and increase
concentrations of serum androstenedione [15,19]. These effects
may be caused either by a centrally mediated modiﬁcation of
GABA-ergic neurotransmission in the hypothalamus or by a direct
effect of VPA on endocrine tissue, in particular in the testis. A direct
effect on the testis is supported by studies in dogs, rats, and goats
that have demonstrated a reduction in testicular size and altered
testicular morphology after VPA treatment [14,19,20]. Similarly,
small testicular volumes have also been found in some [14], but not
all [14], studies of men taking VPA. Further, semen morphology
and motility are affected by VPA. In humans, the number of motile
sperms is reduced, and several morphological parameters are
changed [14,15]. In contrast to ﬁndings with CBZ, sperm from men
that have been treated with VPA have been found to show
increased tail pathology [14]. A number of studies of infertile men
without epilepsy have shown these types of sperm tail abnormali-
ties; bent or coiled sperm tails were found to occur signiﬁcantly
more frequently when pregnancy did not occur [20–22]. These
ﬁndings suggest that sperm tail changes observed with VPA may
affect fertility. Carnitine is important for sperm motility, and
reduced sperm motility has been noted in men on VPA, and in
whom the free versus total carnitine ratio is reduced [23,24].
2.3. Lamotrigine
To date, lamotrigine (LTG) has not been associated with
reproductive endocrine disturbances in men with epilepsy nor
in non-epileptic animals [12,25–28].
2.4. Levetiracetam
The mode of action levetiracetam (LEV) is mostly unknown, and
differs from that of other AEDs. The drug binds to a synaptic vesicle
protein, SV2A, which is widely distributed in the central nervous
system and in most endocrine tissues. In a paper from Harden et al.
[29] from 2010 testosterone levels increased in eight men after LEVtreatment. However, this study was uncontrolled and included a
very heterogeneous group of patients. In a clinical study by
Svalheim [28], 30 men treated with LEV did not differ from controls
regarding reproductive hormones or sexual function. Normal
levels of sexual hormones were also found in a recent Chinese
study by Xiaotian [30], but more sperm abnormalities were
reported in LEV-treated males. Further studies are therefore
needed before any conclusions can be drawn regarding the effects
of LEV on reproductive endocrine function in men.
2.5. Topiramate
Sexual dysfunction has rarely been described in association with
treatment with the newer AEDs, but there has been growing evidence
of a correlation between topiramate (TPM) treatment and erectile
dysfunction [31–33] and dose dependent reversible anorgasmia (both
men and women) [34,35]. A non-hormonal, vasogenic mechanism has
been suggested to explain these associations [33].
3. Reproductive endocrine function in women
3.1. Enzyme-inducing drugs
As in males, EIAEDs in females reduce the free fractions of
steroid hormones, increase SHBG, and may also lower DHEAS. No
consistent abnormalities in basal or stimulated serum gonadotro-
pin or prolactin levels have been reported [36]. The clinical
consequences of these endocrine changes are unknown. To date, no
large study has demonstrated any increased frequency of
menstrual disorders or other reproductive endocrine disorders
in women treated with these drugs [27].
3.2. Valproate
The ﬁrst report suggesting a high incidence of menstrual
disorders linked to obesity, hyperandrogenism, and polycystic
ovaries (PCO) in women taking VPA for epilepsy was published in
1993 by Isoja¨rvi et al. [37]. This was a cross-sectional study of 238
women on VPA monotherapy. These women had signiﬁcantly
more menstrual disorders than controls, and these were frequently
associated with PCO and/or hyperandrogenism. PCO and hyper-
androgenism were especially common if VPA medication had been
started before the age of 20 years. Moreover, the serum mean
androgen levels were increased in women on VPA. These ﬁndings
have been conﬁrmed in later studies [38]. In a large, three-center
study, with patients from Finland, Norway and Netherlands,
hyperandrogenism and/or PCO were detected in 70% of VPA-
treated women, 20% of CBZ-treated women, and 19% of women
acting as controls. Menstrual disorders were reported by 59% of
women on VPA, compared with 12% of CBZ-treated women and
15% women in the control group [39].
The age dependency, found by Isoja¨rvi in 1993 [37] was later
conﬁrmed by others [38]. Furthermore, increases in serum
androgen levels were detected before and during pubertal
development in young girls taking VPA for epilepsy [40]. A ﬁve-
year follow-up of these girls showed that of the girls/women who
were still on VPA 5 years later (during the follow-up study), 60%
had polycystic ovary syndrome (PCOS) as compared with 25% of
the girls/women who had stopped taking VPA and switched to
other AEDs [41]. These observations indicate that the young ovary
is more vulnerable to the effects of VPA.
Similar endocrine changes induced by VPA were also seen in
non-epileptic rats in a long-term monotherapy study [25]. A
signiﬁcant, dose-dependent increase in the number of follicular
cysts in the ovaries was observed after VPA treatment, together
with a reduction in the number of corpora lutea. Blood samples
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decrease in estrogen levels, with an absence of, or only minor,
effects on gonadotropins [42].
Endocrine side effects of VPA have also been seen in women using
VPA for bipolar disorders [43,44]. Endocrine side effects caused by
VPA seem to be at least partly reversible [45,46] (Table 1).
PCO and hyperandrogenism are not only caused by the weight
gain that many VPA users experience, as they also occur in lean
VPA-treated women without hyperinsulinemia [39]. However,
obesity and related hyperinsulinemia can be caused by VPA and
may exacerbate the VPA-related reproductive endocrine disorders
[38].
VPA is thought to have a direct effect on follicular steroidogen-
esis in the ovary. This was studied by Taubøll et al. [47–50], in a
series of studies using both porcine and human ovary cells that
were exposed to different concentrations of VPA, which was shown
to increase testosterone and reduce estradiol secretion. The
conversion of testosterone to estradiol at therapeutically relevant
concentrations was reduced, indicating an effect on aromatase
activity. A direct effect of VPA is further supported by the work of
Hattori et al. [51] who demonstrated the presence of the enzyme
microsomal epoxide hydrolase (mEH) in human ovaries. mEH is
important in detoxiﬁcation of several substances. Hattori and
co-workers showed that human granulosa cells expressed mEH
and that inhibition of mEH suppressed conversion of testosterone
to estradiol. Given that VPA is a mEH inhibitor, this may be a
mechanism by which VPA reduces serum estrogen levels and
thereby increases the testosterone: estrogen ratio. This effect
would result in an androgen-dominant microenvironment in the
ovary and thereby possibly lead to polycystic changes without an
increase in levels of luteinizing hormone.
VPA has also been found to affect gene expression. Nelson-
DeGrave et al. [52] found that VPA increased expression of CYP17
and CYP11A genes. This occurs in PCOS and implies that VPA
treatment may convert normal ovarian theca cells to a PCOS
phenotype. In line with this, Gustavsen et al. [53] used a model of
human adrenal carcinoma cells, which are capable of full
steroidogenesis, to show that VPA resulted in a general down-
regulation of expression of genes encoding for enzymes early in
steroidogenesis. Using the same cell line, gene analyses suggested
that VPA affects NR0BI expression [54], inhibiting promoters of
other genes involved in steroidogenesis. Altered expression of
NR0BI might explain the observed down-regulation in hormone
production.Table 1
Endocrine effects of antiepileptic drugs.
Drug Men Women
EIAED Tot. testosterone $ $
Tot. estradiol $ ("?PHT) $
SHBG " "
FAI # #
DHEAS # #
FSH $ $
LH $ $
VPA Tot. testosterone $ "
Tot. estradiol # (?)
SHBG $ "
Androstenedione $/" "
DHEAS "
FAI $ "
Insulin " "
FSH # $
LH # $
Published with permission from: Taubøll et al. [80].
The table shows the most frequently reported ﬁndings. Differences between studies
do occur. EIAED: enzyme inducing antiepileptic drugs; VPA: valproate; PHT:
phenytoin; FAI: total testosterone/SHBG  100.3.3. Lamotrigine
Lamotrigine has not been found to have endocrine side effects
[26–28,55]. On the contrary, switching from VPA treatment to LTG
treatment resulted in normalization of endocrine function during a
one-year follow-up of women with a previously identiﬁed
reproductive endocrine disorder that was likely to be related to
VPA medication [46].
3.4. Levetiracetam
In a paper from 2006, we showed for the ﬁrst time that LEV
affected basal, but not gonadotropin-stimulated, testosterone and
estrogen secretion from porcine ovarian follicular cells [49]. This
observation suggests that LEV may affect reproductive endocrine
function. The clinical consequences of this observation are difﬁcult
to determine, but it is possible that LEV might only affect
reproductive endocrine function in prepubertal female subjects
with low serum gonadotropin levels, whereas fertile-aged women
might not be at risk because the ovaries are stimulated by higher
levels of gonadotropins. In a paper from 2009, no endocrine
changes were found in 21 LEV-treated women [28].
3.5. New AEDs
Randomized studies on newer AEDs are lacking, and little is
known about their possible endocrine side effects. There have only
been a few case reports, and this provides a positive indication that
such side effects are rare. However, further studies are required.
4. Menstrual regularity
Women with epilepsy generally experience more menstrual
irregularities than healthy women [56]. This is thought to be due
both to the epilepsy itself and to the use of AEDs. Menstrual
disorders are especially frequent in women on VPA treatment and
in women using polytherapy [27,39].
5. Fertility
Fertility rates have been found to be lower in epilepsy patients
than in the general population. In the Rochester study, fertility was
considered to be reduced to 80% in males and 85% in females [57].
However, in a population-based study from Iceland, no difference
in birth rate was found between female epilepsy patients and the
reference group [58]. However, genuine infertility is not easy to
measure in clinical studies because it depends on the frequency of
unprotected intercourse. Social and psychological factors will also
affect birth rate, which, erroneously, is often taken as being
equivalent to fertility. While the frequency of marriage is lower
among epilepsy patients, birth rate is also reduced among the
married patients [59,60]. Epilepsy is a symptom of an underlying
disease in many patients, and it can be that underlying disease
(inherited diseases, cancer, cerebrovascular diseases, etc.) that is
the cause of reduced fertility, rather than the epilepsy itself.
The medication taken for epilepsy can still be of importance. As
previously noted, semen quality in men and ovarian function in
women can be disrupted by AEDs, and changing medication should
be considered for epilepsy patients with genuine fertility
problems.
6. Sexuality
Several studies have shown that sexual problems are common
in people with epilepsy, and a wide range of different problems has
been described [61,62].
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psychological and epileptological factors are probably important. In
a large study on otherwise healthy outpatients on monotherapy and
with few seizures, sexual problems were as frequent in the control
group as in those being treated with LEV or LTG [28]. Psychological
factors and the burden of seizures are probably critical, and for many
patients are probably of greater importance than the drug treatment
itself. Therefore, the speciﬁc role of the different AEDs is difﬁcult to
ascertain. In general, EIAEDs reduce the free fractions of peripheral
sex steroid hormone concentrations, and this is well known to affect
sexual function, including reduced libido, and potency problems in
men. Herzog et al. [12] found reduced sexual function in men using
CBZ or PHT for localization-related epilepsy, while sexual function
was normal in men on LTG. The decreased sexual function in men on
CBZ or PHT correlated with lowered bioactive testosterone levels. In
a paper from Svalheim et al. [28], men and women treated with CBZ
reported being less satisﬁed with their sex lives than those treated
with LEV or LTG. In a randomized study by Mattson et al. [63],
impotence and decreased libido were reported in 16% of epilepsy
patients after starting monotherapy with PB, 12% after starting PHT,
and 13% after starting CBZ.
A few cases of anorgasmia have also been described that are
apparently associated with gabapentin treatment [64]. LTG,
however, was shown not to affect sexual function [12,28,65].
AEDs can affect sexuality through different mechanisms. First,
certain AEDs induce liver enzymes that lead to reductions in the
free fractions of peripheral sex steroid hormones. Second, a more
general, depressive effect of AEDs on brain excitability may have a
negative impact on sexual function. It is possible that the more
sedative AEDs have greater impact in this respect than some of the
newer AEDs with less sedative effects. A negative impact of AEDs
on cognitive function may also be important. In order to obtain a
better understanding of the possible impacts of different AEDs on
sexuality and to elucidate the underlying mechanisms further
research on these aspects is essential.
7. Bone health
In comparison with the general population, patients with
epilepsy have a 2–6 times greater risk of fractures. In a Danish
population-based study from 2004, which included 124,655 fracture
cases and 373,962 controls, the fracture risks related to AED
exposure were examined [66]. In an unadjusted analysis, all AEDs
were associated with an increased risk of fracture. After adjustment
for prior fracture, exposure to corticosteroids, comorbidity, social
variables, and diagnosis of epilepsy, some drugs were signiﬁcantly
associated with increased fracture risk: CBZ (odds ratio (OR): 1.18);
OXC (OR: 1.14), clonazepam (OR: 1.27); PB (OR: 1.79), and VPA (OR:
1.15). For CBZ, PB, OXC, and VPA, a dose–response association was
seen. The risk was more pronounced in those who used EIAEDs than
in those who used non-inducing drugs.
The results from various studies strongly indicate that AED use
may have negative impact on bone health. The older EIAEDs,
particularly phenytoin (PHT), are most consistently associated
with fractures and reduced bone mineral density (BMD). Pack and
Walczak assessed several studies on the effects of individual AEDs
on bones [67]. Decreased BMD was found to be associated with
PHT use in four of ﬁve studies, PB use in two of two studies, and
VPA use in three of four studies. CBZ use was only associated with
low BMD in one of ﬁve studies. Short-lasting treatment with LTG in
93 premenopausal women was apparently not associated with
reduction in BMD or with changes in bone turnover markers.
The traditional theory for explaining the bone loss associated
with EIAEDs is that turnover of vitamin D and its metabolites is
accelerated, owing to increased activity in the cytochrome P-450
system. This results in low vitamin D, reduced intestinalabsorption of calcium, low serum calcium, secondary hyperpara-
thyroidism, decreased BMD, and, eventually, fractures [68,69].
Several AEDs, including PHT, PHB, CBZ, and VPA, also appear to
have a direct effect on bone cells, resulting in increased bone
turnover [67,68,70].
Interaction with vitamin K has also been proposed as a possible
mechanism for osteoporosis in patients with epilepsy. Vitamin K is
an important co-factor in the synthesis of osteocalcin, an
important marker of bone formation. Enzyme-inducing AEDs have
been found to reduce vitamin K levels [71].
EIAEDs may also increase the metabolism of sex steroids,
resulting in decreased levels of bioavailable endogenous estradiol
and testosterone. An increased rate of bone loss may therefore be a
consequence of this increased steroidal metabolism [69,72].
Several other mechanisms have also been suggested. These
include disruption of brain regulation of bone metabolism via
increased leptin [67], AED-induced increase in homocysteine [73],
and reduction in insulin-growth factor 1 [72].
The mechanisms involved in AED-associated bone loss are
likely to be multifactorial and are not yet fully understood. For the
individual patient with epilepsy, the risk of developing bone
disease is probably determined by a combination of several factors,
including genetic factors, epilepsy syndrome, age, gender, lifestyle,
and AED treatment.
8. Thyroid function
Some AEDs are associated with alterations in thyroid function.
This was ﬁrst shown in 1981 by Strandjord et al. [74]. In 42 patients
on long-term CBZ treatment, thyroxine (T4), free T4-index (FT4),
and triiodothyronine (T3) concentrations in serum were found to
be signiﬁcantly lower than in controls, while T3 uptake and
thyrotropin (TSH) concentrations did not differ between patients
and controls. A study of 90 men with epilepsy taking either CBZ,
VPA, or OXC and 25 control men demonstrated that serum T4 and
FT4 concentrations were low in men taking CBZ or OXC, with 45%
and 24% falling below the reference range, respectively, but serum
T3 and TSH levels were normal. In men taking VPA, the
concentrations of thyroid hormones and TSH were normal [75].
Another study in children with new-onset epilepsy [76] was
performed prospectively with baseline thyroid testing prior to
drug administration, followed by testing at 3, 6, and 12 months
after initiation of CBZ or VPA treatment. CBZ-treated patients
demonstrated signiﬁcantly lower serum T4 and FT4 levels than at
baseline evaluation and compared with control subjects, but
normal serum T3 and TSH response in a thyrotropin releasing
hormone (TRH) test. This difference could be identiﬁed after only 3
months treatment. Some of the CBZ-treated children were
withdrawn from CBZ for other reasons, and reevaluation 6 months
later revealed that their thyroid hormone values had normalized.
All values remained normal in the VPA treatment group. The
patients were found to be clinically euthyroid, also in the CBZ
group. The authors conclude that thyroid hormone alterations are
not associated with clinical or subclinical hypothyroidism.
Another study of 35 patients on long-term PHT or CBZ
treatment [77] reported that the mean concentrations of T4,
FT4, FT3, and reverse triiodothyronine (rT3), but not T3, of these
patients were signiﬁcantly lower than those of 19 controls. Clinical
examination of these patients did not reveal clinical signs of
functional hypothyroidism. The authors also assessed response to
thyroxine treatment in a smaller subset of patients, and the clinical
parameters they examined were found to be unchanged after
treatment. On the basis of the data from the cross-sectional and
thyroxine treatment studies, the authors concluded that patients
receiving AEDs chronically are eumetabolic and do not need
thyroxine supplementation.
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showed that FT4, but not FT3, was signiﬁcantly reduced after 8 and
18 months treatment, while TSH was signiﬁcantly increased.
Alterations in thyroid function seem to be reversible after
withdrawal of medication. Lossius et al. [79] showed signiﬁcant
increases in FT4 serum concentrations 4 months after CBZ
withdrawal, in both men and women.
For patients with hypothyreosis prior to initiation of AED
treatment, use of EIAEDs should probably not be recommended.
Otherwise, the clinical importance of the interactions between
AEDs and thyroid hormones appears to be minor, if any.
9. Conclusion
Many AEDs may affect an epilepsy patient’s hormones and this
may result in menstrual disturbances, sexual problems, fertility
difﬁculties, or osteoporosis. In particular, the use of EIAEDs and
VPA has been associated with such side effects. The newer drugs,
however, have been investigated less and, although current data
may imply a lack of such associations, should also be considered
if new symptoms arise after initiation of treatment with such
drugs. Increased awareness of these side effects will improve the
possibility of tailoring treatment regimes to the characteristics of
individual patients, paying particular regard to patient age and
gender.
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